Hims & Hers Health (NYSE:HIMS) Shares Climb 8.5% - Here's Why

Key Points

• Hims & Hers shares rose 8.5% to about $30.46 in mid-day trading, supported by continued demand for weight-loss products, international expansion and AI initiatives.
• The company faces significant risks, including securities-class-action litigation tied to FTC-related allegations, regulatory uncertainty, margin pressure and the possibility of prolonged cash burn.
• Analysts maintain a largely cautious outlook: the consensus rating is Hold with a $32.43 price target. Recent results showed 38.2% year-over-year revenue growth to $753.2 million, but the company missed EPS estimates and reported a net loss.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) rose 8.5% during mid-day trading on Friday. The company traded as high as $30.29 and last traded at $30.4550. 7,747,991 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 23,291,271 shares. The stock had previously closed at $28.06.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Analyst commentary says Hims & Hers’ revenue growth continues to benefit from strong demand for weight-loss products, international expansion and AI-related initiatives. The company may remain attractive to long-term investors despite near-term margin pressure and regulatory uncertainty. Reasons to Retain Hims & Hers Stock in Your Portfolio for Now
• Neutral Sentiment: The company appointed Jon Franklin as chief accounting officer. His technical accounting and controllership experience could strengthen financial reporting infrastructure as Hims & Hers expands, although the management change is not expected to materially alter near-term earnings. Hims & Hers Names Jon Franklin as Chief Accounting Officer
• Negative Sentiment: Several law firms announced or promoted a securities class action against Hims & Hers and certain executives. The case covers investors who bought shares from August 4, 2025, through July 29, 2026, with a November 2, 2026 lead-plaintiff deadline. The litigation stems from allegations related to an FTC complaint and could create legal costs, reputational damage and additional uncertainty, although the allegations have not been proven. Hims & Hers Securities Class Action Alert Bronstein Gewirtz Grossman Class Action Announcement
• Negative Sentiment: Separate commentary raised concerns that Hims & Hers could face a longer period of cash burn. Margin pressure, FDA uncertainty and ongoing investment needs may limit profitability and reduce the valuation investors are willing to pay. Is Hims & Hers Stock Ready for a Longer Cash Burn?

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $25.00 to $26.00 and gave the company a "hold" rating in a research note on Tuesday, August 11th. TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a "hold" rating in a report on Tuesday, August 11th. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Barclays reduced their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating for the company in a report on Friday, August 21st. Finally, JPMorgan Chase & Co. started coverage on shares of Hims & Hers Health in a research report on Friday, September 11th. They issued a "neutral" rating and a $32.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $32.43.

Hims & Hers Health Price Performance

The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The firm has a market cap of $7.18 billion, a PE ratio of -48.92 and a beta of 2.44. The company has a 50 day moving average price of $29.39 and a 200 day moving average price of $28.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period last year, the firm earned $0.17 EPS. The company's quarterly revenue was up 38.2% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 2,000 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the sale, the chief financial officer owned 234,527 shares in the company, valued at approximately $6,965,451.90. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 3,461 shares of the firm's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $29.17, for a total value of $100,957.37. Following the transaction, the insider directly owned 300,809 shares of the company's stock, valued at $8,774,598.53. The trade was a 1.14% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,982 shares of company stock worth $3,630,849 in the last quarter. Corporate insiders own 11.76% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in shares of Hims & Hers Health by 24.0% in the third quarter. GAMMA Investing LLC now owns 5,770 shares of the company's stock valued at $172,000 after buying an additional 1,116 shares during the last quarter. QRG Capital Management Inc. acquired a new stake in Hims & Hers Health during the second quarter worth approximately $248,000. Envestnet Portfolio Solutions Inc. grew its stake in Hims & Hers Health by 46.9% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company's stock worth $1,126,000 after acquiring an additional 10,366 shares during the period. Bienville Capital Management LLC purchased a new stake in Hims & Hers Health in the 2nd quarter worth approximately $27,242,000. Finally, Engineers Gate Manager LP acquired a new position in Hims & Hers Health in the 2nd quarter valued at $232,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.